CytoDyn collaborates with amfAR to accelerate HIV cure research

▴ CytoDyn collaborates with amfAR to accelerate HIV cure research
The amfAR Foundation for AIDS Research, to test the ability of Vyrologix (leronlimab) to mediate a functional HIV cure

CytoDyn Inc., a late-stage biotechnology company developing Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it signed an agreement with amfAR, The Foundation for AIDS Research, to test the ability of Vyrologix (leronlimab) to mediate a functional HIV cure. The international organization, amfAR, plays a vital role in AIDS research by identifying critical gaps in the knowledge of HIV and AIDS and supporting groundbreaking studies.

In 2007, Timothy Brown, also known as the “Berlin patient,” became the first documented person cured of HIV following a stem cell transplant from a CCR5-deficient donor. Subsequent attempts to cure HIV via stem cell transplant from donors expressing CCR5 failed, indicating the critical role of CCR5 deficiency in HIV cure. Last year, Adam Castillejo, formerly the “London patient,” became the second documented case of HIV cure after a stem cell transplant from a CCR5-deficient donor.

While it is now recognized that CCR5 is central to these two documented cases of HIV cure, natural CCR5-deficient individuals are rare and finding such donors is extremely difficult. Recently, Vyrologix (leronlimab) successfully protected macaques from retroviral infection, mirroring the protection from HIV seen in CCR5 deficient individuals. CytoDyn’s partnership with amfAR will advance clinical studies to incorporate Vyrologix to mimic a CCR5-deficient stem cell donor and attempt to functionally cure an HIV+ person receiving a stem cell transplant from a donor expressing CCR5.

“Using leronlimab to pharmacologically copy a CCR5-deficient donor for HIV cure is an exciting next step in our journey towards a cure for the 38 million people living with HIV,” stated Kevin Robert Frost, Chief Executive Officer at amfAR. “While a stem cell transplant is unlikely to be rolled out as an HIV cure, demonstrating that leronlimab can functionally phenocopy CCR5 deficiency and replicate the London and Berlin patients would be a major advancement.” As part of the agreement, CytoDyn will provide leronlimab and study support, while amfAR will support groundbreaking study sites to incorporate leronlimab in their cure studies.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We are honored to be in partnership with amfAR and the opportunities to accelerate a search for an HIV cure using this scientific premise. Timothy Brown’s cure ignited hope that a cure can happen through bone marrow transplant from the rare individuals with a delta-32 mutation. The success in our animal studies for HIV with Vyrologix (leronlimab) has provided this opportunity. We are very excited to be supporting this project, and to be a part of this groundbreaking endeavor with amfAR.”

Tags : #CytoDynInc #LatestNewsonCytoDynInc24thNov #amfARFoundation #LatestNewsonamfARFoundation24thNov #LatestPharmaNews24thNov #LatestPharmaCollaboration24thNov #LatestResearchonAIDS #LatestResearonAIDS24thNov #BoneMarrowTransplant

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Worldwide EndoMarch, Endo Run to raise mass awareness on Endometriosis!February 21, 2024
Uptick In Respiratory, and Cardiac Problems Due To Poor Air Quality In DelhiFebruary 21, 2024
Evidence shows risks associated with energy drinks in childrenFebruary 21, 2024
iHub-Data at IT-Hyderabad announces collaborative initiative with technical institutions for AI/ML training programsFebruary 20, 2024
Viatris Receives Global Minimized Risk of Antimicrobial Resistance Certification, Advancing its Commitment to Responsible Antibiotic ProductionFebruary 20, 2024
“Kusum Ka Biyaah” Indian Hindi film based on a true story releasing on 1st March 2024February 19, 2024
Introducing Moscow's Pioneering Initiative: An Open Dataset for AI-driven Brain Disease Detection"February 19, 2024
ICPA Health Products Introduces Coolora Spray - A Rapid Relief Solution For Oral & Throat DiscomfortFebruary 19, 2024
Section 43B of the Income Tax demystifiedFebruary 16, 2024
Nutricircle Introduces Health Supplements My45NutrientsTM to Enhance Overall Well-beingFebruary 16, 2024
YFLO organised a session “Design Your Story” to inspire young FICCI Ladies to design their own compelling storiesFebruary 15, 2024
149 experts call to find all TB to stop TBFebruary 15, 2024
ICPA Welcomes Global Leader In Periodontal Aesthetics - Prof Giovanni Zucchelli On His Inaugural Visit To IndiaFebruary 14, 2024
Fast Fashion and Sustainability are not friends and do not go well with each other: Namrata Joshipura, one of India’s most celebrated Fashion designers February 14, 2024
YFLO to organise a session Design Your StoryFebruary 14, 2024
Starkey Launches Genesis AI Hearing Aids in India, Pioneering a New Era in Hearing HealthFebruary 14, 2024
Indian Institute of Heritage and University of Birmingham announce strategic partnershipFebruary 14, 2024
Siddharth Anand’s Fighter emerges as the first hit of 2024February 13, 2024
India’s 26 years old youth’s Adventurous Atal Yatra to Celebrate Silver Jubilee of the Golden Quadrilateral beginsFebruary 13, 2024
Vitafoods India 2024 - Exploring Nutraceutical FrontiersFebruary 13, 2024